Thông tin thuốc gốc
Chỉ định và Liều dùng
Metastatic medullary thyroid carcinoma, Unresectable locally advanced medullary thyroid carcinoma
Adult: 300 mg once daily, continue until disease progression or unacceptable toxicity. Dose reduction, dosing interruption, or discontinuation may be required according to individual safety or tolerability (refer to detailed product guideline). Missed dose should not be taken if within 12 hours of next dose.
Suy thận
CrCl (mL/min) Dosage
Not recommended.
200 mg once daily.
Suy gan
Not recommended.
Cách dùng
May be taken with or without food. Swallow whole, do not chew/crush. For patients w/ difficulty swallowing, disperse tab in ½ glass plain, non-carbonated water & stir for approx 10 min. No other liqd should be used. Swallow immediately after dispersion. Mix remaining residue w/ ½ glass water & swallow. Liqd dispersion may also be administered through nasogastric or gastrotomy tubes.
Chống chỉ định
Patient with QTc interval over 480 milliseconds, congenital long QTc syndrome. Concomitant use with drugs prolonging QTc interval. Pregnancy and lactation.
Thận trọng
Patient with brain metastases, history of torsades de pointes, haemoptysis. Hepatic and renal impairment.
Tác dụng không mong muốn
Significant: Diarrhoea, hypothyroidism, hypertension, hypertensive crisis, reversible posterior leukoencephalopathy syndrome (RPLS), rash, photosensitivity reactions, palmar-plantar erythrodysaesthesia, elevated ALT.
Eye disorders: Corneal abnormalities, blurred vision, halo vision, photopsia, glaucoma, conjunctivitis, dry eye, keratopathy.
Gastrointestinal disorders: Colitis, nausea, abdominal pain, vomiting, dyspepsia, dry mouth.
General disorders and admin site conditions: Fatigue, pyrexia, asthenia, pain, oedema.
Hepatobiliary disorders: Cholelithiasis.
Infections and infestations: Sepsis, influenza, furuncle, fungal infection.
Metabolism and nutrition disorders: Decreased appetite, hyperglycaemia, hypocalcaemia, hypokalaemia, dehydration, hyponatremia.
Musculoskeletal and connective tissue disorders: Muscle spasm.
Nervous system disorders: Headache, dysgeusia, paraesthesia, dysaesthesia, dizziness, tremor, lethargy, loss of consciousness, balance disorder.
Psychiatric disorders: Depression, insomnia, anxiety.
Renal and urinary disorders: Proteinuria, UTI, nephrolithiasis, dysuria, haematuria, cystitis, pyelonephritis.
Respiratory, thoracic and mediastinal disorders: Upper respiratory tract infection, nasopharyngitis, bronchitis, pneumonia, sinusitis, laryngitis, epistaxis, haemoptysis.
Skin and subcutaneous tissue disorders: Dermatitis acneiform, acne, dry skin, photosensitivity reactions, pruritus, alopecia, nail abnormalities, folliculitis.
Potentially Fatal: Torsades de pointes, QT prolongation, ventricular tachycardia, heart failure, severe skin reactions (e.g. toxic epidermal necrolysis, Stevens-Johnson syndrome), interstitial lung disease, pneumonitis, ischaemic cerebrovascular events, severe haemorrhage.
Thông tin tư vấn bệnh nhân
This drug may cause fatigue and blurred vision, if affected, do not drive or operate machinery. Limit exposure to sunlight.
Chỉ số theo dõi
Monitor serum electrolytes (e.g. Ca, Mg, K), TSH, and ECG (QT interval) at baseline, at 2-4 weeks, at 8-12 weeks, and every 3 months thereafter. Monitor renal and hepatic function, blood pressure. Assess for signs and symptoms of heart failure, RPLS, pulmonary and skin toxicities.
Tương tác
Decreased plasma concentration with potent CYP3A4 inducers (e.g. dexamethasone, carbamazepine, phenytoin, phenytoin, phenobarbital, rifabutin, rifampicin). Increased plasma concentration of metformin, digoxin.
Potentially Fatal: Increased risk of torsades de pointes with antiarrhythmic drugs (e.g. amiodarone, disopyramide, dofetilide, procainamide, sotalol) and other drugs prolonging QTc interval (e.g. mizolastine, moxifloxacin, cisapride, arsenic, erythromycin IV, toremifene).
Tương tác với thức ăn
May decrease serum concentration with St John’s wort.
Tác dụng
Description: Vandetanib is a tyrosine kinase inhibitor that blocks intracellular signalling, angiogenesis and cellular proliferation through inhibition of epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), rearranged during transfection (RET) tyrosine kinase, protein tyrosine kinase 6 (BRK), TIE, EPH kinase receptor and SRC kinase receptors.
Absorption: Slowly absorbed. Time to peak plasma concentration: Approx 6 hours (range: 4-10 hours).
Distribution: Volume of distribution: Approx 7,450 L. Plasma protein binding: Approx 90%, mainly to albumin and α1-acid glycoprotein.
Metabolism: Metabolised in the liver by CYP3A4 enzyme to N-desmethylvandetanib, and by flavin-containing mono-oxygenase enzymes FMO1 and FMO3 to vandetanib-N-oxide.
Excretion: Mainly via faeces (approx 44%); urine (approx 25%). Elimination half-life: Approx 19 days.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Vandetanib, CID=3081361, (accessed on Jan. 23, 2020)

Bảo quản
Store at 25°C.
This is a cytotoxic drug. Follow applicable procedures for receiving, handling, administration, and disposal.
Phân loại MIMS
Liệu pháp nhắm trúng đích
Phân loại ATC
L01EX04 - vandetanib ; Belongs to the class of other protein kinase inhibitors. Used in the treatment of cancer.
Tài liệu tham khảo
Anon. Vandetanib. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. Accessed 27/03/2018.

Anon. Vandetanib. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 27/03/2018.

Buckingham R (ed). Vandetanib. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 27/03/2018.

Caprelsa Tablet (AstraZeneca Pharmaceuticals LP). DailyMed. Source: U.S. National Library of Medicine. Accessed 27/03/2018.

Joint Formulary Committee. Vandetanib. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 27/03/2018.

Preston CL (ed). Interactions of Vandetanib. Stockley’s Drug Interactions [online]. London. Pharmaceutical Press. Accessed 16/04/2018.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Vandetanib từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in